Clinical spectrum of dopa-responsive dystonia and related disorders

Current Neurology and Neuroscience Reports

Volumn 14, Issue 7, 2014, Pages

  Lee, Woong Woo ^a,b   Jeon, Beom Seok ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Dopa responsive dystonia; Dopaminetransporter; DRD plus; GTP cyclohydrolase I; Tyrosinehydrolase; Vesicular monoamine transporter

Indexed keywords

BIOPTERIN; DOPAMINE TRANSPORTER; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; NEOPTERIN; PHENYLALANINE; TETRAHYDROBIOPTERIN; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; ALCOHOL DEHYDROGENASE; SEPIAPTERIN REDUCTASE; SLC18A2 PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER;

CLINICAL FEATURE; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOPA RESPONSIVE DYSTONIA; DOPAMINERGIC SYSTEM; DRUG RESPONSE; DYSTONIA; ENZYME ASSAY; GCH 1 GENE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; LOW DRUG DOSE; MOLECULAR PATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ONSET AGE; PARKINSONISM; REVIEW; TIC; TREATMENT PLANNING; DYSTONIC DISORDERS; GENETICS; MUTATION; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY;

ALCOHOL OXIDOREDUCTASES; DIAGNOSIS, DIFFERENTIAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSTONIC DISORDERS; GTP CYCLOHYDROLASE; HUMANS; MUTATION; PARKINSONIAN DISORDERS; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84901356754     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0461-9     Document Type: Review

References (99)

1. Segawa M, Ohmi K, Itoh S, Aoyama M, Hayakawa H. Childhood basal ganglia disease with marked response to L-Dopa: hereditary progressive basal ganglia disease with marked diurnal fluctuation. Shinryo. 1972;24:667-72.
2. Beck D. Dystonia musculosum deformans with another case in the same family. Proc R Soc Med. 1947;40:551-2.
3. Corner BD. Dystonia musculorum deformans in siblings: treated with artane (trihexyphenidyl). Proc R Soc Med. 1952;45(7):451-2.
4. Rajput AH. Levodopa in dystonia musculosum deformans. Lancet. 1973;1:432.
5. Ouvrier RA. Progressive dystonia with marked diurnal fluctuation. Ann Neurol. 1978;4(5):412-7. doi:10.1002/ana.410040505. (Pubitemid 9030383)
6. Gordon N. Fluctuating dystonia and allied syndromes. Neuropediatrics. 1982;13(3):152-4. doi:10.1055/s-2008-1059614. (Pubitemid 12055004)
7. Kumammoto I, Nomoto M, Yoshodome M, Osame M, Igata A. Five cases of dystonia with marked diurnal fluctuation and special reference to homovanillic acid in CSF. Clin Neurol (Tokyo). 1984;24:697-702. (Pubitemid 14026733)
8. Sunohara N, Mano Y, Ando K, Satoyoshi E. Idiopathic dystonia-parkinsonism with marked diurnal fluctuation of symptoms. Ann Neurol. 1985;17(1):39-45. doi:10.1002/ana.410170110. (Pubitemid 15156049)
9. Deonna T. DOPA-sensitive progressive dystonia of childhood with fluctuations of symptoms-Segawa's syndrome and possible variants. Results of a collaborative study of the European Federation of Child Neurology Societies (EFCNS). Neuropediatrics. 1986;17(2):81-5. (Pubitemid 16061161)
10. Nygaard TG, Duvoisin RC. Hereditary dystonia-parkinsonism syndrome of juvenile onset. Neurology. 1986;36(11):1424-8. (Pubitemid 17175763)
11. de Yebenes JG, Moskowitz C, Fahn S, Saint-Hilaire MH. Longterm treatment with levodopa in a family with autosomal dominant torsion dystonia. Adv Neurol. 1988;50:101-11.
12. Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv Neurol. 1988;50:377-84.
13. Kim JW, Cho GS, Myung HJ. Two families of diurnally fluctuating hereditary progressive dystonia. J Korean Neurol Assoc. 1990;8:389-92.
14. Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Doparesponsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology. 1990;40(1):66-9. (Pubitemid 20032895)
15. Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, et al. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in doparesponsive dystonia. Ann Neurol. 1998;43(6):792-800. doi:10.1002/ana.410430614. (Pubitemid 28280223)
16. Jeon BS, Jeong JM, Park SS, Lee MC. Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopamine deficiency. In: Fahn S, Marsden CD, DeLong M, editors. Dystonia 3: advances in neurology, vol. 78. Philadelphia: Lippincott-Raven; 1998. p. 309-17.
17. Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev. 2000;22 Suppl 1:S65-80. (Pubitemid 30662464)
18. .• Kim HJ, Jeon BS, Yang HJ, Cho JY. In need of something better than sleep. Lancet. 2013;381(9866):598. doi:10.1016/S0140-6736(12)61892-3. This article showed that the remarkable sleep benefit can occur in postencephalitic parkinsonism as well as in dopa-responsive dystonia.
19. Yamamura Y, Hattori N, Matsumine H, Kuzuhara S, Mizuno Y. Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification. Brain Dev. 2000;22 Suppl 1:S87-91. (Pubitemid 30662466)
20. Chung SJ, Park HK, Ki CS, Kim MJ, Lee MC. Marked diurnal fluctuation and rest benefit in a patient with Parkin mutation. Mov Disord. 2008;23(4):624-6. doi:10.1002/mds.21951.
21. Nygaard TG, Waran SP, Levine RA, Naini AB, Chutorian AM. Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol. 1994;11(3):236-40. (Pubitemid 24363090)
22. Nygaard TG, Takahashi H, Heiman GA, Snow BJ, Fahn S, Calne DB. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia.Ann Neurol. 1992;32(5):603-8. doi:10.1002/ana.410320502.
23. Chaila EC, McCabe DJ, Delanty N, Costello DJ, Murphy RP. Broadening the phenotype of childhood-onset dopa-responsive dystonia. Arch Neurol. 2006;63(8):1185-8. doi:10.1001/archneur.63.8.1185. (Pubitemid 44232330)
24. Furukawa Y, Kish SJ, Bebin EM, Jacobson RD, Fryburg JS, Wilson WG, et al. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I genemutations. Ann Neurol. 1998;44(1): 10-6. doi:10.1002/ana.410440107. (Pubitemid 28323650)
25. Harwood G, Hierons R, Fletcher NA, Marsden CD. Lessons from a remarkable family with dopa-responsive dystonia. J Neurol Neurosurg Psychiatry. 1994;57(4):460-3. (Pubitemid 24118142)
26. Tassin J, Durr A, Bonnet AM, Gil R, Vidailhet M, Lucking CB, et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain. 2000;123:1112-21. (Pubitemid 30312104)
27. Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol. 2003;54 Suppl 6:S32-45. doi:10.1002/ana.10630. (Pubitemid 36903852)
28. Furukawa Y, Mizuno Y, Narabayashi H. Early-onset parkinsonism with dystonia. Clinical and biochemical differences from hereditary progressive dystonia or DOPA-responsive dystonia. Adv Neurol. 1996;69:327-37.
29. Furukawa Y, Shimadzu M, Rajput AH, Shimizu Y, Tagawa T, Mori H, et al. GTP-cyclohydrolase I gene mutations in hereditary progressive and dopa-responsive dystonia. Ann Neurol. 1996;39(5):609-17. doi:10.1002/ana. 410390510.
30. Blau N, Bonafe L, Thony B. Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of dopa-responsive dystonia and sepiapterin reductase deficiency. Mol Genet Metab. 2001;74(1-2):172-85. doi:10.1006/mgme.2001.3213. (Pubitemid 32955158)
31. Hyland K, Gunasekara RS, Munk-Martin TL, Arnold LA, Engle T. The hph-1 mouse: a model for dominantly inherited GTP-cyclohydrolase deficiency. Ann Neurol. 2003;54 Suppl 6:S46-8. doi:10.1002/ana.10695. (Pubitemid 36903853)
32. Furukawa Y, Kapatos G, Haycock JW, Worsley J, Wong H, Kish SJ, et al. Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia. Ann Neurol. 2002;51(5):637-41. doi:10.1002/ana.10175.
33. Rajput AH, Gibb WR, Zhong XH, Shannak KS, Kish S, Chang LG, et al. Dopa-responsive dystonia: pathologic and biochemical observations in a case. Ann Neurol. 1994;35(4):396-402. doi:10.1002/ana.410350405. (Pubitemid 24107845)
34. Sawle GV, Leenders KL, Brooks DJ, Harwood G, Lees AJ, Frackowiak RS, et al. Dopa-responsive dystonia: [18F] dopa positron emission tomography. Ann Neurol. 1991;30(1):24-30. doi: 10.1002/ana.410300106.
35. Okada A, Nakamura K, Snow BJ, Bhatt MH, Nomoto M, Osame M, et al. PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). In: Nagatsu T, Yanagisawa N, Mizuno Y, editors. Advances in neurology, vol. 60. New York: Raven; 1993. p. 591-4.
36. Snow BJ, Nygaard TG, Takahashi H, Calne DB. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol. 1993;34(5):733-8. doi:10.1002/ana.410340518. (Pubitemid 23333248)
37. Thony B, Blau N. Mutations in the GTP cyclohydrolase I and 6- pyruvoyl-tetrahydropterin synthase genes. Hum Mutat. 1997;10(1): 11 - 20. doi:10.1002/(SICI)1098-1004(1997)10:1<11::AIDHU.
38. Hyland K, Nygaard TG, Trugman JM, Swoboda KJ, Arnold LA, Sparagana SP. Oral phenylalanine loading profiles in symptomatic and asymptomatic gene carriers with dopa-responsive dystonia due to dominantly inherited GTP cyclohydrolase deficiency. J Inherit Metab Dis. 1999;22(3):213-5. (Pubitemid 29259478)
39. Saraiva JM, Seakins JW, Smith I. Plasma phenylalanine and tyrosine levels revisited in heterozygotes for hyperphenylalaninaemia. J Inherit Metab Dis. 1993;16(1):105-9. (Pubitemid 23114303)
40. Saunders-Pullman R, Blau N, Hyland K, Zschocke J, Nygaard T, Raymond D, et al. Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. Mol Genet Metab. 2004;83(3):207-12. doi:10.1016/j.ymgme. 2004.07.010. (Pubitemid 39473062)
41. Furukawa Y, Nishi K, Kondo T, Mizuno Y, Narabayashi H. CSF biopterin levels and clinical features of patients with juvenile parkinsonism. In: Nagatsu T, Yanagisawa N, Mizuno Y, editors. Advances in neurology, vol. 60, vol. 60. New York: Raven; 1993. p. 562-7.
42. Takahashi H, Levine RA, Galloway MP, Snow BJ, Calne DB, Nygaard TG. Biochemical and fluorodopa positron emission tomographic findings in an asymptomatic carrier of the gene for doparesponsive dystonia. Ann Neurol. 1994;35(3):354-6. doi:10.1002/ana.410350317. (Pubitemid 24089660)
43. Blau N, Joller P, Atares M, Cardesa-Garcia J, Niederwieser A. Increase of GTP cyclohydrolase I activity in mononuclear blood cells by stimulation: detection of heterozygotes of GTP cyclohydrolase I deficiency. Clin Chim Acta. 1985;148(1):47-52. (Pubitemid 15036681)
44. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet. 1994;8(3):236-42. doi:10.1038/ng1194-236. (Pubitemid 24338734)
45. Bonafe L, Thony B, Leimbacher W, Kierat L, Blau N. Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem. 2001;47(3):477-85. (Pubitemid 32222462)
46. Hirano M, Tamaru Y, Nagai Y, Ito H, Imai T, Ueno S. Exon skipping caused by a base substitution at a splice site in the GTP cyclohydrolase I gene in a Japanese family with hereditary progressive dystonia dopa responsive dystonia. Biochem Biophys Res Commun. 1995;213(2):645-51. doi:10.1006/bbrc.1995.2180.
47. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993;90(24):11965-9. (Pubitemid 24008761)
48. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993;34(3):423-31. doi:10.1002/ana.410340331. (Pubitemid 23259619)
49. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46(1):231-7.
50. Bandmann O, Nygaard TG, Surtees R, Marsden CD, Wood NW, Harding AE. Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum Mol Genet. 1996;5(3):403-6. (Pubitemid 26069585)
51. Furukawa Y, Lang AE, Trugman JM, Bird TD, Hunter A, Sadeh M, et al. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology. 1998;50(4):1015-20. (Pubitemid 28212831)
52. Suzuki T, Ohye T, Inagaki H, Nagatsu T, Ichinose H. Characterization of wild-type and mutants of recombinant human GTP cyclohydrolase I: relationship to etiology of dopa-responsive dystonia. J Neurochem. 1999;73(6):2510-6.
53. Hagenah J, Saunders-Pullman R, Hedrich K, Kabakci K, Habermann K, Wiegers K, et al. High mutation rate in doparesponsive dystonia: detection with comprehensive GCHI screening. Neurology. 2005;64(5):908 - 11. doi:10.1212/01.WNL.0000152839.50258.A2.
54. Zirn B, Steinberger D, Troidl C, Brockmann K, von der Hagen M, Feiner C, et al. Frequency of GCH1 deletions in Dopa-responsive dystonia. J Neurol Neurosurg Psychiatry. 2008;79(2):183-6. doi:10.1136/jnnp.2007.128413. (Pubitemid 351236551)
55. Hahn H, Trant MR, Brownstein MJ, Harper RA, Milstien S, Butler IJ. Neurologic and psychiatric manifestations in a family with a mutation in exon 2 of the guanosine triphosphate-cyclohydrolase gene. Arch Neurol. 2001;58(5):749-55. (Pubitemid 32423047)
56. Mori S, Matsuyama K, Kohyama J, Kobayashi Y, Takakusaki K. Neuronal constituents of postural and locomotor control systems and their interactions in cats. Brain Dev. 1992;14(Suppl):S109-20.
57. Levitt P, Harvey JA, Friedman E, Simansky K, Murphy EH. New evidence for neurotransmitter influences on brain development. Trends Neurosci. 1997;20(6):269-74. (Pubitemid 27261459)
58. Komori H, Matsuishi T, Yamada S, Ueda N, Yamashita Y, Kato H. Effect of age on cerebrospinal fluid levels of metabolites of biopterin and biogenic amines. Acta Paediatr. 1999;88(12):1344-7. (Pubitemid 30012555)
59. Hwu WL, Wang PJ, Hsiao KJ, Wang TR, Chiou YW, Lee YM. Dopa-responsive dystonia induced by a recessive GTP cyclohydrolase I mutation. Hum Genet. 1999;105(3):226-30.
60. Jarman PR, Bandmann O, Marsden CD, Wood NW. GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs. J Neurol Neurosurg Psychiatry. 1997;63(3): 304-8. (Pubitemid 27412369)
61. Yeung WL, Wong VC, Chan KY, Hui J, Fung CW, Yau E, et al. Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency. J Child Neurol. 2011;26(2):179 - 87. doi:10.1177/0883073810377014.
62. Ribases M, Serrano M, Fernandez-Alvarez E, Pahisa S, Ormazabal A, Garcia-Cazorla A, et al. A homozygous tyrosine hydroxylase gene promoter mutation in a patient with dopa-responsive encephalopathy: clinical, biochemical and genetic analysis. Mol Genet Metab. 2007;92(3):274-7. doi:10.1016/j.ymgme. 2007.07.004. (Pubitemid 47513565)
63. Hoffmann GF, Assmann B, Brautigam C, Dionisi-Vici C, Haussler M, de Klerk JB, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol. 2003;54 Suppl 6:S56-65. doi:10.1002/ana.10632. (Pubitemid 36903855)
64. Ludecke B, Knappskog PM, Clayton PT, Surtees RA, Clelland JD, Heales SJ, et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet. 1996;5(7):1023-8. (Pubitemid 26232286)
65. Schiller A, Wevers RA, Steenbergen GC, Blau N, Jung HH. Longterm course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology. 2004;63(8):1524-6. (Pubitemid 39426298)
66. Ludecke B, Dworniczak B, Bartholome K. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. Hum Genet. 1995;95(1):123-5.
67. Swaans RJ, Rondot P, Renier WO, Van Den Heuvel LP, Steenbergen-Spanjers GC, Wevers RA. Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism. Ann Hum Genet . 2000;64:25 - 31. doi:10.1017/S0003480000007922.
68. Bonafe L, Thony B, Penzien JM, Czarnecki B, Blau N. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninaemia. Am J Hum Genet. 2001;69(2):269-77. doi:10.1086/321970. (Pubitemid 32695200)
69. Steinberger D, Blau N, Goriuonov D, Bitsch J, Zuker M, Hummel S, et al. Heterozygous mutation in 5'-untranslated region of sepiapterin reductase gene (SPR) in a patient with doparesponsive dystonia. Neurogenetics. 2004;5(3):187-90. doi:10.1007/s10048-004-0182-3. (Pubitemid 39361972)
70. Neville BG, Parascandalo R, Farrugia R, Felice A. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain. 2005;128:2291-6. doi:10.1093/brain/awh603. (Pubitemid 41407969)
71. Abeling NG, Duran M, Bakker HD, Stroomer L, Thony B, Blau N, et al. Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. Mol Genet Metab. 2006;89(1 - 2): 116-20. doi:10.1016/j.ymgme.2006.03. 010.
72. Echenne B, Roubertie A, Assmann B, Lutz T, Penzien JM, Thony B, et al. Sepiapterin reductase deficiency: clinical presentation and evaluation of long-term therapy. Pediatr Neurol. 2006;35(5):308-13. doi:10.1016/j. pediatrneurol.2006.05.006. (Pubitemid 44636123)
73. Friedman J, Hyland K, Blau N, MacCollin M. Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology. 2006;67(11):2032-5. doi:10.1212/01.wnl.0000247274.21261.b4. (Pubitemid 44967384)
74. Arrabal L, Teresa L, Sanchez-Alcudia R, Castro M, Medrano C, Gutierrez-Solana L, et al. Genotype-phenotype correlations in sepiapterin reductase deficiency. A splicing defect accounts for a new phenotypic variant. Neurogenetics. 2011;12(3):183-91. doi: 10.1007/s10048-011-0279-4.
75. Friedman J, Roze E, Abdenur JE, Chang R, Gasperini S, Saletti V, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012;71(4):520-30. doi:10.1002/ana.22685.
76. •• Kurian MA, Li Y, Zhen J, Meyer E, Hai N, Christen HJ, et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol. 2011;10(1):54-62. doi:10.1016/S1474-4422(10)70269-6. This report describes newly recognized transportopathy with mutation in the dopamine transporter gene (SLC6A3). The children with dopamine transporter deficiency showed very similar symptoms to those of the DRD-plus patients. We should consider transportopathies in managing patients with DRD-plus manifestation.
77. •• Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med. 2013;368(6):543-50. doi:10.1056/NEJMoa1207281. Rilstone, et al. reported a family with mutation in SLC18A2, which encodes vesicular monoamine transporter 2. The affected members showed symptoms related to the dysfunction of dopamine, serotonin, and epinephrine/norepinephrine. This is another transportopathy presenting as DRD-plus. We should consider transportopathies in managing the patients with DRD-plus manifestation.
78. Van Hove JL, Steyaert J, Matthijs G, Legius E, Theys P, Wevers R, et al. Expanded motor and psychiatric phenotype in autosomal dominant Segawa syndrome due to GTP cyclohydrolase deficiency. J Neurol Neurosurg Psychiatry. 2006;77(1):18-23. doi:10.1136/jnnp.2004.051664. (Pubitemid 43022684)
79. Yaltho TC, Jankovic J, Lotze T. The association of Tourette syndrome and dopa-responsive dystonia. Mov Disord. 2011;26(2):359-60. doi:10.1002/mds.23424.
80. Bandmann O, Valente EM, Holmans P, Surtees RA, Walters JH, Wevers RA, et al. Dopa-responsive dystonia: a clinical and molecular genetic study. Ann Neurol. 1998;44(4):649-56. doi:10.1002/ana.410440411. (Pubitemid 28477853)
81. Regula JU, Thoden U, Meinck HM. Adult-onset dystonia: atypical manifestation of Segawa disease.Mov Disord. 2007;22(9):1335-7. doi:10.1002/mds.21377. (Pubitemid 47325046)
82. • Lee JY, Yang HJ, Kim JM, Jeon BS. Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with doparesponsive dystonia. Parkinsonism Relat Disord. 2013;19(12):1156-9. doi:10.1016/j. parkreldis.2013.08.003. This is a report on Korean DRD cases with classic manifestations. All the patients were shown to have mutations in GCH-1. Of note is that the initial report (reference 15) failed to show mutation in GCH-1 in some of them, while they were predicted to have mutation in GCH-1 because of low CSF neopterin level.
83. • Tadic V, Kasten M, Bruggemann N, Stiller S, Hagenah J, Klein C. Dopa-responsive dystonia revisited: diagnostic delay, residual signs, and nonmotor signs. Arch Neurol. 2012;1-5. doi:10.1001/archneurol.2012.574. The authors reported high frequencies of residual motor signs in treated DRD patients, which is inconsistent with our experience (reference 82) and our prediction that L-dopa should reverse motor symptoms (other than contractures) completely.
84. Van Gerpen JA. Dopa-responsive dystonic camptocormia. Neurology. 2006;66(11):1779. doi:10.1212/01.wnl.0000218158.61678.55. (Pubitemid 43964648)
85. Schneider SA, Mohire MD, Trender-Gerhard I, Asmus F, Sweeney M, Davis M, et al. Familial dopa-responsive cervical dystonia. Neurology. 2006;66(4):599 - 601. doi:10.1212/01.wnl.0000198501.61063.66.
86. • Charlesworth G, Mohire MD, Schneider SA, Stamelou M, Wood NW, Bhatia KP. A taxia telangiectasia presenting as dopa-responsive cervical dystonia. Neurology. 2013;81(13):1148-51. doi:10.1212/WNL.0b013e3182a55fa2. This is a very peculiar family with doparesponsive cervical dystonia and mutation in ataxia-telangiectasia gene. The relation between L-dopa responsiveness and mutation in ataxia-telangiectasia is questionable considering reference 87, where dystonia did not respond to L-dopa in tested patients.
87. Saunders-Pullman R, Raymond D, Stoessl AJ, Hobson D, Nakamura K, Pullman S, et al. Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. Neurology. 2012;78(9):649 - 57. doi:10.1212/WNL. 0b013e3182494d51.
88. Ichinose H, Inagaki H, Suzuki T, Ohye T, Nagatsu T. Molecular mechanisms of hereditary progressive dystoniawithmarked diurnal fluctuation. Segawa's disease. Brain Dev. 2000;22 Suppl 1:S107-10. (Pubitemid 30662469)
89. Wider C, Melquist S, Hauf M, Solida A, Cobb SA, Kachergus JM, et al. Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: redefining DYT14 as DYT5. Neurology. 2008;70(16):1377-83. doi:10.1212/01.wnl. 0000275527.35752.c5. (Pubitemid 351521928)
90. Nagata E, Kosakai A, Tanaka K, Segawa M, Fujioka H, Shintaku H, et al. Dopa-responsive dystonia (Segawa disease) -like disease accompanied by mental retardation: a case report. Mov Disord. 2007;22(8):1202-3. doi:10.1002/mds. 21517. (Pubitemid 47067238)
91. Hjermind LE, Johannsen LG, Blau N, Wevers RA, Lucking CB, Hertz JM, et al. Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord. 2006;21(5):679-82. doi:10.1002/mds.20773. (Pubitemid 43792750)
92. Kikuchi A, Takeda A, Fujihara K, Kimpara T, Shiga Y, Tanji H, et al. Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report. Mov Disord. 2004;19(5):590-3. doi:10.1002/mds. 10712.
93. Ichinose H, Ohye T, Matsuda Y, Hori T, Blau N, Burlina A, et al. Characterization of mouse and human GTP cyclohydrolase I genes. Mutations in patients with GTP cyclohydrolase I deficiency. J Biol Chem. 1995;270(17):10062- 71.
94. Eggers C, Volk AE, Kahraman D, Fink GR, Leube B, Schmidt M, et al. Are Dopa-responsive dystonia and Parkinson's disease related disorders? A case report. Parkinsonism Relat Disord. 2012;18(5):666-8. doi:10.1016/j.parkreldis. 2011.10.003.
95. Nygaard TG. Dopa-responsive dystonia: delineation of the clinical syndrome and clues to pathogenesis. In: Nagatsu T, Yanagisawa N, Mizuno Y, editors. Advances in neurology, vol. 60. New York: Raven; 1993. p. 577-85.
96. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology. 1991;41(2):174-81.
97. Turjanski N, Bhatia K, Burn DJ, Sawle GV, Marsden CD, Brooks DJ. Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia. Neurology. 1993;43(8):1563-8. (Pubitemid 23230544)
98. Jellinger K. Juvenile-onset parkinsonism: same patient reported twice. Neurology. 1992;42(5):1124-5.
99. Clot F, Grabli D, Cazeneuve C, Roze E, Castelnau P, Chabrol B, et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain. 2009;132:1753-63. doi:10.1093/brain/awp084.